Abstract
AbstractAL002 is an investigational, humanized monoclonal antibody that targets triggering receptor on myeloid cells 2 (TREM2) and is currently under development for the treatment of early Alzheimer’s disease. The INVOKE‐2 trial is an ongoing global Phase 2 randomized, double‐blind, placebo‐controlled study to evaluate the efficacy and safety of AL002 in participants with early Alzheimer’s disease. This presentation will provide an update on AL002 clinical development.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Alzheimer's & Dementia: The Journal of the Alzheimer's Association
Paper Title
Journal
Date
